HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Masataka Sata Selected Research

Heparin Cofactor II

10/2012Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway.
10/2009Heparin cofactor II as a novel vascular protective factor against atherosclerosis.
4/2009Heparin cofactor II is an independent protective factor against peripheral arterial disease in elderly subjects with cardiovascular risk factors.
6/2007Strain-dependent embryonic lethality and exaggerated vascular remodeling in heparin cofactor II-deficient mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Masataka Sata Research Topics

Disease

49Atherosclerosis
11/2021 - 12/2003
38Inflammation (Inflammations)
03/2022 - 06/2003
26Ischemia
01/2018 - 07/2002
20Coronary Artery Disease (Coronary Atherosclerosis)
11/2021 - 01/2005
19Hypertension (High Blood Pressure)
12/2019 - 06/2010
16Neoplasms (Cancer)
11/2021 - 10/2002
16Neointima
12/2020 - 10/2002
15Cardiovascular Diseases (Cardiovascular Disease)
11/2021 - 12/2010
15Heart Failure
01/2021 - 05/2003
15Hyperplasia
02/2014 - 08/2002
14Type 2 Diabetes Mellitus (MODY)
01/2021 - 01/2013
14Insulin Resistance
01/2021 - 02/2010
13Atherosclerotic Plaque (Atheroma)
11/2019 - 01/2008
13Vascular Remodeling
04/2013 - 04/2002
12Obesity
01/2020 - 04/2004
11Myocardial Infarction
01/2019 - 05/2004
10Body Weight (Weight, Body)
12/2021 - 07/2004
10Vascular System Injuries
02/2018 - 08/2002
9Fibrosis (Cirrhosis)
01/2021 - 10/2002
9Diabetes Mellitus
01/2021 - 01/2011
8Thrombosis (Thrombus)
07/2020 - 06/2009
7Myocardial Ischemia (Ischemic Heart Diseases)
01/2022 - 10/2002
7Carotid Artery Diseases
01/2020 - 04/2009
7Acute Coronary Syndrome
03/2019 - 08/2014
6Atrial Fibrillation
01/2022 - 04/2010
6Arteriosclerosis
01/2016 - 10/2004
5Dyslipidemias (Dyslipidemia)
01/2021 - 01/2011
5Pulmonary Arterial Hypertension
11/2015 - 01/2007
5Vascular Diseases (Vascular Disease)
02/2014 - 09/2003
4Venous Thromboembolism
07/2022 - 01/2018
4Hyperlipidemias (Hyperlipidemia)
03/2022 - 01/2011
4Hyperuricemia
01/2022 - 07/2011
4Left Ventricular Dysfunction
01/2021 - 12/2009
4Rupture
01/2019 - 09/2011
4Stroke (Strokes)
08/2017 - 12/2007
4Hypercholesterolemia
06/2017 - 08/2002
4Metabolic Syndrome (Dysmetabolic Syndrome X)
05/2016 - 02/2010
4Essential Hypertension
01/2015 - 01/2009

Drug/Important Bio-Agent (IBA)

18Apolipoproteins E (ApoE)IBA
11/2021 - 07/2005
18ApolipoproteinsIBA
11/2021 - 08/2002
18LipidsIBA
11/2021 - 12/2009
18Angiotensin IIIBA
01/2021 - 10/2002
15Biomarkers (Surrogate Marker)IBA
01/2021 - 10/2009
15Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
03/2019 - 06/2004
13Proteins (Proteins, Gene)FDA Link
12/2015 - 12/2005
10Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
07/2013 - 05/2004
8Eicosapentaenoic AcidIBA
03/2019 - 04/2008
7DNA (Deoxyribonucleic Acid)IBA
03/2022 - 05/2004
7Glucose (Dextrose)FDA LinkGeneric
01/2021 - 01/2013
7Docosahexaenoic AcidsIBA
03/2019 - 12/2014
7Pharmaceutical PreparationsIBA
01/2017 - 01/2011
7Nitric Oxide (Nitrogen Monoxide)FDA Link
07/2013 - 04/2008
6AnticoagulantsIBA
07/2022 - 06/2013
6CollagenIBA
10/2018 - 08/2004
6AdipokinesIBA
01/2018 - 08/2010
5RivaroxabanIBA
07/2022 - 10/2015
5Triglycerides (Triacylglycerol)IBA
12/2021 - 06/2011
5CanagliflozinIBA
01/2021 - 04/2016
5Factor Xa (Coagulation Factor Xa)IBA
01/2021 - 10/2015
5Uric Acid (Urate)IBA
01/2020 - 07/2011
5CholesterolIBA
01/2019 - 12/2007
5LDL CholesterolIBA
01/2015 - 02/2010
5Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
01/2014 - 05/2004
5Telmisartan (Micardis)FDA Link
01/2014 - 01/2009
5Type 1 Angiotensin ReceptorIBA
12/2010 - 01/2005
4Messenger RNA (mRNA)IBA
01/2022 - 04/2005
4HDL CholesterolIBA
12/2021 - 05/2013
4Brain Natriuretic Peptide (Natrecor)FDA Link
01/2021 - 12/2014
4LigandsIBA
01/2020 - 12/2005
4SodiumIBA
01/2020 - 07/2016
4Sodium-Glucose Transporter 2 InhibitorsIBA
01/2020 - 01/2016
4Dipeptidyl-Peptidase IV InhibitorsIBA
11/2019 - 08/2015
4oxidized low density lipoproteinIBA
01/2019 - 02/2010
4Toll-Like Receptors (Toll-Like Receptor)IBA
01/2019 - 03/2011
4Toll-Like Receptor 9IBA
01/2019 - 12/2013
4Ezetimibe (Zetia)FDA Link
01/2018 - 02/2010
4ThrombinFDA Link
01/2018 - 06/2007
4CytokinesIBA
01/2018 - 08/2009
4Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
10/2017 - 12/2014
4AdiponectinIBA
01/2017 - 10/2002
4CreatinineIBA
01/2017 - 01/2004
4HDL LipoproteinsIBA
10/2015 - 04/2007
4erucylphosphocholineIBA
09/2015 - 08/2009
4AldosteroneIBA
08/2014 - 04/2005
4Angiotensin II Type 1 Receptor BlockersIBA
01/2014 - 01/2005
4ONO 1301IBA
01/2013 - 07/2009
4Heparin Cofactor IIIBA
10/2012 - 06/2007
4Angiotensin Receptor AntagonistsIBA
01/2012 - 11/2007
3edoxabanIBA
07/2022 - 01/2018
3InterferonsIBA
03/2022 - 05/2015
3FebuxostatFDA Link
01/2022 - 06/2016

Therapy/Procedure

31Therapeutics
07/2020 - 04/2002
9Stents
03/2019 - 02/2005
8Transplantation
10/2018 - 08/2003
6Bone Marrow Transplantation (Transplantation, Bone Marrow)
12/2015 - 07/2005
5Percutaneous Coronary Intervention
11/2021 - 10/2009
4Cardiac Rehabilitation
10/2018 - 01/2014
4Heart Transplantation (Grafting, Heart)
02/2007 - 10/2004
3Drug Therapy (Chemotherapy)
05/2022 - 06/2013
3Catheter Ablation
01/2022 - 01/2011